Core Insights - The forum titled "2025 China International Medical Health Industry Development and Investment Forum" was held in Beijing, focusing on creating a high-standard international service trade cooperation platform [2] - China's pharmaceutical and health industry is transitioning to a high-quality development phase, with significant growth in foreign investment and collaboration across various sectors [2] - In 2024, China's pharmaceutical innovation licensing transactions exceeded $52.26 billion, establishing the country as a leader in the global pharmaceutical asset licensing market [2] - The integration of AI, big data, and digital technologies is accelerating the development of China's pharmaceutical industry, providing new momentum for high-quality growth [2] Industry Developments - The "Implementation Plan for the Digital and Intelligent Transformation of the Pharmaceutical Industry (2025-2030)" was released by seven government departments, emphasizing the importance of digital transformation for high-quality development [3] - The plan outlines two key development goals: significant progress in digital transformation by 2027 and comprehensive coverage of digital transformation among large-scale pharmaceutical enterprises by 2030 [4] Expert Insights - Industry experts highlighted the strong penetration of AI in the healthcare sector, with active investment and financing in "AI + healthcare" initiatives, particularly in drug development, medical imaging, and smart health management [5] - Challenges such as liability in AI healthcare, algorithm bias, and data privacy protection need to be addressed for the successful application of AI in healthcare [5] - The fusion of natural healing and AI technology is seen as a key to breaking through industry barriers, enabling traditional medical wisdom to leverage modern technology for broader applications [5]